There are currently 301 active clinical trials seeking participants for Cancer research studies. The states with the highest number of trials for Cancer participants are California, Texas, New York and Florida.
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: California Cancer Associates for Research and Excellence, Inc. (cCare), Encinitas, California +13 locations
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Register for Updates
Decision Making for Older Adults With Cancer
NCT05374304
Recruiting
This is a minimal risk, pilot cluster randomized controlled trial (CRT) to determine the feasibility and acceptability of training medical oncologists to use the Best Case/Worst Case-Geriatric Oncology (BC/WC-GeriOnc) communication tool in clinical practice with older adults with cancer.
Gender:
All
Ages:
65 years and above
Trial Updated:
09/12/2023
Locations: Zuckerberg San Francisco General Hospital, San Francisco, California +2 locations
Conditions: Cancer
Register for Updates
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: City of Hope, Duarte, California +11 locations
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Register for Updates
Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT05588141
Recruiting
Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed. Objective: To see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations. Eligibility: People aged 18 years and older with diffuse gliomas that returned after treatment. They must also have mutations in the IDH1 or IDH2 gene... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/08/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Brain Tumor, Cancer
Register for Updates
Patient-Reported Outcome Version of the Common Criteria for Adverse Events
NCT04050072
Recruiting
Childhood cancer survivors are vulnerable to treatment-related late effects, including physical and psychosocial morbidities, subsequent malignancies, and premature death. Symptom assessment provides a unique insight into survivorship care since symptoms not only indicate the manifestation for the occurrence of chronic health conditions, but also impact quality of life and survival. The National Cancer Institute (NCI) has developed a Patient-Reported Outcomes version of the Common Terminology Cr... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
09/06/2023
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Survivorship, Cancer
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California +30 locations
Conditions: Myocarditis Acute, Cancer
Register for Updates
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
NCT05833360
Recruiting
Cancer strikes about one in three women and one in two men in the U.S. and more than 600,000 die from it each year. The best chance to reduce these numbers and save lives is through early detection and intervention. The investigators are developing a blood test to detect cancer from a simple blood draw also referred to as a liquid biopsy. This test is based on orphan non-coding RNAs (oncRNAs) that are abundant in the blood of patients with cancer and largely absent in people without cancer. Usi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Exai Bio Inc., Palo Alto, California
Conditions: Cancer
Register for Updates
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
NCT05550948
Recruiting
Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning. Primary Objective To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/05/2023
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: ALL, Hodgkin Lymphoma, Cancer, Survivorship
Register for Updates
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
NCT02253251
Recruiting
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/27/2023
Locations: MiraKind, Los Angeles, California
Conditions: Cancer
Register for Updates
Biomarkers of Immune-Related Toxicity
NCT03409016
Recruiting
This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
08/21/2023
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: Cancer, Metastatic Cancer
Register for Updates
Arizona Cancer Center Biospecimen Repository
NCT00896935
Recruiting
RATIONALE: Collecting and storing samples of tissue and blood from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing tumor, tissue, and blood samples from patients with pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona
Conditions: Cancer
Register for Updates
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
NCT05082610
Recruiting
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or without pembrolizumab, in patients with advanced solid tumors (i.e., locally advanced and unresectable, or metastatic).
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: The City of Hope National Medical Center, Duarte, California +5 locations
Conditions: Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor
Register for Updates